Included in the formulation
АТХ:R.03.B.B Holinblockers
Pharmacodynamics:Selectively blocks m-holinoretseptory muscles of the bronchi.Has a pronounced and prolonged bronchodilator effect. Promotes thickening of phlegm.
Pharmacokinetics:After inhalation, the therapeutic effect develops in 15-30 minutes and lasts for 4-5 hours.
Does not penetrate the blood-brain barrier.
Indications:It is used for the treatment of diseases and cupping of conditions leading to bronchospasm: pneumonia, emphysema, bronchial asthma. It is used for the purpose of diagnosis of latent bronchospastic syndrome.
X.J10-J18.J15 Bacterial pneumonia, not elsewhere classified
X.J10-J18.J15.9 Bacterial pneumonia, unspecified
X.J40-J47.J43 Emphysema
X.J40-J47.J44 Other chronic obstructive pulmonary disease
X.J40-J47.J45 Asthma
X.J999.J999 * Diagnosis of respiratory diseases
Contraindications:Closed-angle glaucoma, age up to 3 years, pregnancy and lactation, individual intolerance.
Carefully:A productive cough, age over 40 years - the risk of undiagnosed glaucoma.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inhalation, in an initial dose of 40 mcg (one press on the valve of an aerosol can containing 12.5 mg). It is possible to increase the single dose to achieve a clinical effect to 80 mcg (one press on the valve of an aerosol can containing 25 mg) and 160 μg. The interval between admission is 4-6 hours.
The highest daily dose: 480 mcg.
The highest single dose: 160 mcg.
Side effects:Digestive system: Perspiration in the throat, dry mouth.
Sense organs: increased intraocular pressure, spasm of accommodation, impaired vision.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described. Compatible with any bronchodilators and glucocorticoids.
Special instructions:When taking the drug is not recommended driving and working with moving machinery.